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Abstract
The role of rare genetic variation in the etiology of complex disease remains unclear. However, the development of next-
generation sequencing technologies offers the experimental opportunity to address this question. Several novel statistical
methodologies have been recently proposed to assess the contribution of rare variation to complex disease etiology.
Nevertheless, no empirical estimates comparing their relative power are available. We therefore assessed the parameters
that influence their statistical power in 1,998 individuals Sanger-sequenced at seven genes by modeling different
distributions of effect, proportions of causal variants, and direction of the associations (deleterious, protective, or both) in
simulated continuous trait and case/control phenotypes. Our results demonstrate that the power of recently proposed
statistical methods depend strongly on the underlying hypotheses concerning the relationship of phenotypes with each of
these three factors. No method demonstrates consistently acceptable power despite this large sample size, and the
performance of each method depends upon the underlying assumption of the relationship between rare variants and
complex traits. Sensitivity analyses are therefore recommended to compare the stability of the results arising from different
methods, and promising results should be replicated using the same method in an independent sample. These findings
provide guidance in the analysis and interpretation of the role of rare base-pair variation in the etiology of complex traits
and diseases.
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Introduction
There is growing evidence that rare variants contribute to the
etiology of complex diseases [1,2,3,4]. A striking difference in the
distributions of the odds ratios (ORs) for common and rare
variants has been illustrated in a wide range of recent publications,
favoring higher ORs for some rare variants (reviewed elsewhere
[5,6,7]). As well, it has been demonstrated that rare coding
variants associated with complex traits are sometimes causal
through amino acid substitution [3,8,9]. For these reasons, rare
variants hold promise as a source of heritability which is not
explained by common base-pair variants.
Identifying rare variants associated with disease requires large
sample sizes since few individuals harbor such polymorphisms. In
addition, for rare variants, the power of single-marker tests, such as
those performed by genome-wide association studies (GWAS), is
poor. Development of alternative methods is thus essential. Over the
past two years, a growing body of methods [2,10,11,12,13,14,15,16,
17,18,19,20] seeking to overcome this limitation has emerged. These
methods generally employ three main strategies: collapsing markers
across a region, weighting and/or prioritizing markers, and
distribution-based approaches.
Li and Leal [20], for example, proposed a method to collapse
rare variants across a region. This and other collapsing methods
are based upon the hypothesis that low-frequency variants are
rare, but in aggregate, they may be common enough to account
for variation in common traits. Under such models, it is assumed
that the probability of being diseased increases with the number of
rare minor alleles. However, this might not always be the case
[21]. Weighting methods assign more importance to alleles based
on many possible criteria, such as minor allele frequency (MAF) in
the control population [17], or possible alterations in protein
function, including measures produced by SIFT and Polyphen2
[11,22]. More recently, methods examining changes in distribu-
tions associated with rare variants [2,23] have been proposed. Liu
and Leal [2] based their novel method on multi-locus genotypic
configurations, where each unique pattern of genotypes is
tabulated, and the associated risk of disease for each configuration
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method as a kernel-based approach (KBAC), since part of the
mixture distribution is modeled by nonparametric kernel density
estimation. Neale et al. [23] showed that a test of association can
be based on binomial over-dispersion of variance, conditional on
the number of rare variants present in a region. Another
innovative and flexible method has been developed by Wu et al
[24]. These authors proposed the sequence kernel association test
(SKAT), a supervised, flexible, and computationally efficient
regression model (with the possibility of adjusting for covariates),
to test the association between rare and common variants and
traits or disease status. SKAT is similar to a classical mixed model,
and is based on a score test for non-zero variance associated with
the effects of all the rare variants under consideration.
These recently proposed models have often relied upon
unverifiable (and sometimes unnecessary) hypotheses in order to
simulate sequence data. Certainly, simulation of large sets of
sequence data is a complex task and depends on hypotheses
concerning the evolution of human genomic regions. The validity
of any particular set of evolutionary hypotheses is unlikely to be
consistently true across the [4] genome, as each gene demonstrates
a large variance in these parameters [25,26].
The performance of these newly proposed models using real
sequence data in a large sample has not been independently
evaluated. We therefore tested the power of commonly-used
statistical methods designed to assess the impact of rare variants on
continuous and dichotomous traits in 1,998 individuals Sanger-
sequenced at seven genes. We employed a variety of possible
relationships between genotype and phenotype in order to fully
investigate the performance of such models under different
realistic scenarios.
We selectively chose some of the recently proposed statistical
methods for rare variant association. These included: collapsing
methods (with and without a variable minor allele frequency
[MAF] threshold for defining rare variants), a weighting method
(which assigns weights variants inversely proportional to their
MAF), a variance-based approach [2,11,17], as well as a regression
method using the Kernel association test (SKAT) [24]. We used
the software provided by [11] to implement the collapsing and
weighting methods. Four models were first investigated: a
collapsing method using a threshold of 1% (T1) and 5% (T5), a
weighted approach (WE), and a variable-threshold approach (VT)
(see http://genetics.bwh.harvard.edu/rare_variants). (Note that
while the WE method was implemented by [11], the model was
proposed by Madsen and Browning [17]). In addition, we
developed an approach for detection of rare-variant association
with continuous traits that was inspired by KBAC [2], that we call
‘‘weighted outlier detection’’ (WOD). Two different MAF
thresholds were applied to this new WOD method at 1%
(WOD1) and 5% (WOD5) (see Text S1 for details). The last
method we tested is the regression model (SKAT) developed by
[24]. The relative power of each of these methods was then
compared assuming different possible relationships between rare
variants and continuous traits or disease status.
Results
We evaluated the comparative power of recently proposed rare
variant association methods using Sanger sequencing data from
1,998 individuals.
Control simulations
The first set of simulations, which are designed to act as positive
and negative controls for each of the methods tested, assesses
potential relationships between rare variants and continuous traits
under the relevant hypotheses made in several models. Scenario 1
is a ‘‘null model’’, which serves as a negative control. Scenario 2
acts as a positive control for all collapsing models. Scenario 3
depicts a mixture of rare and common variants. Scenario 4 is a
positive control for SKAT and WOD, which are designed to
perform well under a mixture of protective and deleterious
variants. Scenarios 5 and 6 are positive controls for WE. Details
for these six different scenarios are found in Table 1. (See Text S1
for additional information).
Figure 1 shows the average power of each method based on this
control set of simulations from all seven genes (Table 2 and
Table 3). The power is around 5% in the null scenario, as
expected, where no associations were assumed between the
variants and continuous trait. On the other hand, Scenario 2,
referred to as a positive control for the collapsing design,
demonstrates power of 100%. It was expected that this latter
scenario would lead to very high power, since the simulation
assumed that the phenotypes were always altered if the individual
carried at least one rare allele, such as would be expected with a
highly penetrant allele.
In the remaining scenarios, it is striking that all methods have
relatively poor power under most hypotheses, even though our
simulation design included large shifts in the mean phenotype in a
large number of individuals. Almost all of these scenarios show
power less than 50% in the majority of the methods. In scenario 3,
the addition of common causal variants to the presence of rare
causal variants did not improve the power, except for the SKAT
method which demonstrates its advantage when combining
common and rare variants. In Scenario 4, where bidirectional
causal variants are present, only WOD1 and SKAT have power
above 50%.
Scenarios 5 and 6 test performance when rarer variants have
stronger effects. While the VT method marginally outperforms the
WE method in these scenarios, the WE method improves
considerably when compared to the other scenarios where no
relationship was assumed between MAF and effect.
These results demonstrate that all methods perform well under
their intended hypothesized relationship between rare variants and
Author Summary
There is now evidence that rare variants can contribute to
the etiology of complex disease. Next generation sequenc-
ing technologies have enabled their detection in large
cohorts, and new statistical methods have been proposed
to ascertain their association with complex diseases and
traits in order to improve power over single-marker
analysis. Each of these new methods assumes a particular
nature of the relationship between rare variants and
complex disease, yet these hypotheses have been largely
unverified. Therefore we sought to compare the power of
commonly used and novel statistical methods for rare
variants using Sanger sequencing data from 1,998
individuals sequenced at 7 genes by simulating several
phenotypes under models spanning a spectrum of the
common hypotheses concerning such associations. While
all methods perform reasonably well under their own
model-specific hypotheses, no single method gives
consistently acceptable power when these hypotheses
are violated. Unlike GWAS, wherein all variants can often
be tested using the same method across the entire
genome, the analysis and interpretation of sequencing
studies will therefore be considerably more challenging.
Power of Rare Variant Methods
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departure from this main hypothesis.
We next assessed to what extent power is influenced by the
effect size and proportion of causal rare variants. In the next set of
simulations, we varied these two parameters to explore more
systematically how much they influence the strength of the signal
between genes and complex traits. The proportions of causal
variants varied from 10, 15, 20, and 30% of all rare variants,
where the causal variants were chosen at random from the
polymorphisms that had low frequency (i.e., MAF#1%). We
assumed seven possible values for the mean effects: 0.5, 0.75, 1,
1.25, 1.5, 2, and 2.5 standard deviations.
Table 1. Summary of phenotype simulations and hypotheses.
Condition to be
selected as a causal
rare variants Assumption
Number of causal
variants
Mean effect size if
carrying allele from a
causal variant
Scenario 1
Null
NONE No association NA 0
Scenario 2
Positive control for collapsing models
MAF,0.01 At least one causal rare implies
deleterious
at least one rare 21.64
Scenario 3
Mixture of rare and common SNPs
MAF,0.01 Causal SNPs are deleterious 4 rare and 4 common 21.64 or 20.07
Scenario 4
Positive control for SKAT and WOD:
Mixture of protective and deleterious
SNP
MAF,0.01 15% causal SNPs:
7.5% deleterious, 7.5%
protective
15% 21.64 or +1.64
Scenario 5
Positive control for Weighting
with sampling 1/MAF
No restriction Causal SNPs are deleterious,
sampling with probability 1/MAF
10% of rare SNPs Largest effect: 22.5
Effect proportional to 1/MAF
Scenario 6
Positive control for Weighting with
uniform sampling
No restriction idem 9, sampling of causal
SNP is uniform
10% of all SNPs Largest effect: 22.5
Effect proportional to 1/MAF
doi:10.1371/journal.pgen.1002496.t001
Figure 1. Power across all methods, per scenario, as described in Table 1, for the average across the seven genes. Footnote: Note that
in some scenarios, different methods overlap. This is the case for scenario 1 and 2, where all methods give similar power.
doi:10.1371/journal.pgen.1002496.g001
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The combination of seven effects, four proportions of causal
variants associated with the trait, and seven genes, leads to 196
scenarios. In these scenarios, we first analyzed the results of each
scenario using single-marker tests, and then next applied the seven
rare variant methods (T1, T5, VT, WE, WOD1, WOD5, and
SKAT) for gene-level analysis. Next, we applied all seven methods
to dichotomous traits, created by selecting from the extreme
quarters of the continuous trait distribution.
Single-marker tests for rare variants
Results here are restricted to analysis only of the assigned causal
variants, and we report the proportion of these causal variants that
reach statistical significance, after adjustment for multiple-testing,
using a Bonferroni correction. Figure 2 shows the relationship
between the proportion of causal variants assigned and their effect,
averaged across all seven genes. Notably, but as expected, single-
marker tests cannot identify more than 20% of the causal variants,
even when effects are as large as 1.5 standard deviations. Power is
particularly poor when the effect is 0.5 or 0.75 standard deviations.
Systematic simulations for continuous traits
Figure 3 shows the relationship between power, effect size, and
proportion of causal variants associated with a continuous trait,
averaged across all seven genes. Each dot represents the power of a
given method ordered by average effect (ranging from 0.5 to 2.5
standard deviations) within each bin. Each bin represents the
proportion of causal variants (ranging from 10 to 30%). Each of
these 28 scenarios (7 different effect times 4 proportions of causal
variants) can also be expressed in terms of proportion of variance
explained, as seen in Table 4. These values indicate how much
variability in the trait each simulated model explains. It is clear
that none of the proposed methods have strong power to detect
any gene when rare causal variants have small-to-moderate effects
(less than 1.25 standard deviations). For most methods, effects of
1.5 standard deviations are needed to have reasonable power to
detect an association. The power for most methods was less than
60%. Furthermore, our WOD method is not well powered for
small-to-moderate effects, but is comparable to other methods
when the effects are larger. Power tends to increase as the
proportion of causal variant increases, mainly because there are
more causal variants that can possibly influence phenotype. Note
also that WOD does not accommodate covariates but that it
remains possible to incorporate covariates into the phenotype by
using residuals.
Collapsing methods do not perform well when effects are small
or moderate (,1.5 standard deviations). The only situation where
the power was greater than 75% is when between 15% and 30%
of the rare variants are causal, and effects are moderate-to-large
(Figure 3). The SKAT method seemed to perform as well as most
methods for smaller proportion of causal variants, but underper-
forms as the proportion of causal variants increases.
We also evaluated the power of the rare variant methods when
rare variants are assigned to have either deleterious or protective
effects (Figure 4). In this set, we permitted half the causal variants
to be deleterious and half to be protective. Again, the assigned
absolute effects ranged from 0.5 to 2.5 standard deviations and the
proportion of causal variants ranged from 10–30%. Figure 4
clearly shows the substantial advantage of SKAT and our
distribution-based approach (WOD) to detect effects in this
context. In the case of WOD, however, this advantage is limited
to effects of more than 1.5 standard deviations. SKAT does
perform better than WOD when the mean effect is small, but this
advantage tends to disappear for larger effects, e.g., over 2.0 SD.
When individuals carrying causal alleles have phenotypes shifted
by less than 1.25 standard deviation, all methods, except SKAT
performed equally poorly. In these situations SKAT provides
clearly improved power, but absolute power remains relatively
low. These results clearly show the important contribution of
methods that can account for mixture of protective and deleterious
variants within a gene.
Systematic simulations for dichotomous traits
In order to assess the performance of these methods for
dichotomous traits, we selected 500 cases and 500 controls from
the extreme 25
th percentiles of the continuous trait distributions.
Table 2. Description of the seven genes.
Total number of
variants in the gene
Number of rare
variants (MAF,1%) Median MAF
Mean percentage of missing
genotype per variant
Coding length (Base
pairs)
Gene 1 49 42 2.50E-04 4.9 2002
Gene 2 103 90 2.54E-04 3.9 4094
Gene 3 29 27 2.52E-04 11.2 1239
Gene 4 64 54 5.08E-04 3.9 1638
Gene 5 68 62 2.54E-04 2.9 1963
Gene 6 67 54 5.08E-04 4.1 2901
Gene 7 128 105 5.01E-04 7.2 1500
doi:10.1371/journal.pgen.1002496.t002
Table 3. Description of the count of rare variants per gene.
Number of individuals with different counts of rare
variants
0 1 2 345
Gene 1 1882 112 4 0 0 0
Gene 2 1707 223 34 4 1 0
Gene 3 1905 74 2 0 0 0
Gene 4 1719 240 9 0 0 0
Gene 5 1771 176 20 2 0 0
Gene 6 1735 223 10 0 1 0
Gene 7 1709 262 24 2 0 1
doi:10.1371/journal.pgen.1002496.t003
Power of Rare Variant Methods
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sampling designs targeting more extremes of the distribution.
Figure 5 shows the relationship between power, effects, and
proportion of causal variants associated with a dichotomous trait,
when causal rare variants only increase risk of disease, averaged
across all seven genes. Note that WOD was not designed for
dichotomous traits, so results from this model are not presented in
this section.
Again, power increases as the proportion of causal variants
increases, and power remains low for smaller effects. In this
particular case-control design, VT appears to have the lowest
power compared to all other methods. The remaining methods,
T1, T5, WE, and SKAT have power estimates that are in a similar
range, but power from T1, T5, and WE seemed to outperform
SKAT as the proportion of causal variants increases. Interestingly,
power does not seem to be as strongly influenced by the magnitude
of the effect, as is it for continuous trait results. This can be explain
by the fact that when the effect is one SD away from the mean, on
average, over 90% of the individuals that are carrying a causal
allele will have their phenotype shifted and be classified as cases. In
other words, between effects of 1 to 2.5 SD, there is not a large
difference in the number of shifted individuals that are correctly
classified as cases.
The power was low for almost all methods when causal variants
could be either deleterious or protective––as was observed for
continuous traits. Figure 6 shows the relationship between power,
effects, and proportion of causal variants associated with a
dichotomous trait, when causal variants are deleterious, or
protective, averaged across all seven genes. Power increases as
the proportion of causal variants increases, and we also observe the
‘‘plateau’’ pattern described in the previous paragraph. Methods
such as T1, T5, and WE that are not designed for a mixture of
deleterious and protective effects have poor power to detect any
association between genes and dichotomous traits. SKAT clearly
outperforms the other methods under these circumstances.
Discussion
While many large-scale sequencing studies are now underway to
identify rare variants associated with complex diseases and traits,
our results demonstrate that assessing the association between rare
variants and complex disease is a challenging task. Standard
single-marker association methods exhibit low power and the
power of the statistical methods tailored for rare variants varies
tremendously depending on the true nature of the relationship
between the rare genetic variants and the phenotype. These
findings provide guidance in the design, analysis and interpretation
of sequencing studies for complex disease.
As it is still unknown how rare variants influence complex
disease, we have simulated several phenotypes under models
spanning a spectrum of the common hypotheses concerning such
associations. It is likely that the nature of the relationship between
rare variants and a phenotype varies from gene-to-gene. Our
findings suggest that no single method gives consistently acceptable
Figure 2. Proportion of causal variants reaching significance as a function of the average effect and proportion of causal variants
on average in a gene, employing a SNP-by-SNP analysis.
doi:10.1371/journal.pgen.1002496.g002
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sample size. Analysis using different methods clearly imposes an
additional multiple testing burden, which cannot be easily
addressed. One, though somewhat cumbersome, way to solve this
problem would be by derivation of empirical P-values taking into
account the variety of methods tested. Another, more straightfor-
ward, approach would be to undertake replication in an
independent sample, using the method which demonstrated best
results at the discovery stage.
In this paper, we have also developed a new method
conceptually based on Liu and Leal’s KBAC method [2] to detect
the association between rare variants and quantitative traits. Our
extension of [2] is implemented in R and is available from the
authors. We have also developed a simulation framework to
compare all major novel statistical methods to identify the
contribution of rare variants to continuous phenotypes under
identical conditions. Our new approach performs poorly if all rare
variants act in the same direction, but performs well when variants
can either increase or decrease phenotype and have large effect.
We note that the presence of randomly assigned rare variants of
smaller effect in size, all tests have a distribution of test statistics
that follows the null distribution (see Text S1).
Collapsing methods demonstrate increasing power when the
trait varies with an increasing number of rare alleles. However,
examples exist where protective and deleterious rare alleles are
present in a gene [21], and in such situations, collapsing methods
do not perform well. On the other hand, SKAT and WOD
performed extremely well compared to other methods in the
continuous traits scenarios, and dichotomous traits (SKAT only)
scenarios, respectively. SKAT in particular, was the only method
that performed well for dichotomous traits when variants could be
protective or deleterious. Methods like WE that assign more
weight to rarer alleles are promising, but only if the gene harbors
several causal variants whose effects are each inversely propor-
tional to their MAF. However, we note that the VT method still
outperforms WE even when employing this assumption.
Our study also provides empirical data to judge the value of
dichotomizing a continuous trait and sequencing only its extremes.
While our design included the extreme quarters of the distribution,
thereby eliminating the need to sequence half the study population
and consequently reducing sequencing costs substantially, we note
Figure 3. Continuous traits: Relationship between effect size, proportion of causal variants, and power. All causal variants have a
deleterious effect. Each box corresponds to a different proportion of causal variants involved in the relationship between rare variants and
continuous traits (from left to right, 10, 15, 20 and 30%). On the x-axis, effect sizes are in standard deviations and correspond to the absolute value of
the average size effect.
doi:10.1371/journal.pgen.1002496.g003
Table 4. Proportion of variance explained by rare variants.
0.5 SD 0.75 SD 1.0 SD 1.25 SD 1.5 SD 2.0 SD 2.5 SD
10% of
causal
0.005 0.012 0.022 0.034 0.049 0.086 0.135
15% of
causal
0.008 0.018 0.032 0.051 0.073 0.129 0.202
20% of
causal
0.011 0.024 0.043 0.067 0.097 0.172 0.269
30% of
causal
0.016 0.036 0.064 0.100 0.144 0.256 0.400
doi:10.1371/journal.pgen.1002496.t004
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particularly only when the proportion of causal variants was high
and the effect sizes moderate. Nonetheless, sampling of the
extremes remains an attractive study design, particularly if the
sampled population is large and a more extreme sub-population is
selected.
Methods have been proposed to weight the relative importance
of rare variants based on various parameters including their
estimated deleterious effect on protein function [17,27]. For
example, the incorporation of estimated functional information,
such as the potential effect of an amino acid change as estimated
by Polyphen or SIFT, might improve power. However, these
scores have been criticized for their high level of misclassification
[22]. Moreover, functional prediction is more challenging when
the variants are non-coding.
The spectrum and frequencies of rare genetic variants are
known to depend on ancestry and age of the population studied
[28]. In this work, we have assumed that our sample consists of a
homogeneous population without stratification into population
subgroups. All the methods that we have examined could find false
associations if population sub-strata existed and were associated
with the phenotype, therefore particular attention must be paid to
population structure when designing rare variant studies.
One of the strengths of our study is the use of Sanger
sequencing data, rather than simulated genotyping data. We have
been able to avoid the simulation of such data by using fully
Sanger-sequenced data on nearly 2,000 individuals at seven
genes. Therefore, no genotypic hypotheses were made to
generate the sequence data. Furthermore, the sample size
employed is among the largest sequenced datasets in the world
at present. Despite the fact that gene 3 had more missing data
and fewer variants, we note that the power results derived from
this gene are similar to all other genes.
We note that our simulations assumed no additive effects when
an individual carries multiple rare variants. However, we note that
very few individuals carry 2 or more rare variants (Table 3). In
addition, we assumed that rare variant effects take precedence
over common variant effects.
In light of our results, we recommend that single-marker tests
should not be used alone when rare variants are present and are
assumed to have small-to-moderate effects on the trait of interest.
On the other hand, as power across all novel rare variants methods
is generally low, the potential for identifying rare variant
associations using gene-based analysis strategies requires improve-
ment. Ideally, the true underlying nature of the association
between the gene and the phenotype should determine the choice
of statistical method, however, this relationship is almost always
unknown. Therefore, performing sensitivity analyses, i.e., assessing
different methods that perform differently under various condi-
tions might be a helpful option in order to interpret the results.
Furthermore we suggest that if one method identifies a gene of
interest that replication of this result should be performed in an
independent sample using the same statistical method. All methods
seemed to perform adequately under their specific model
hypotheses, but do not perform as well when these hypotheses
are violated.
Figure 4. Continuous traits: Relationship between effect size, proportion of causal variants, and power, when causal variants are a
mixture of protective and deleterious effects. Each box corresponds to a different proportion of causal variants involved in the relationship
between rare variants and continuous traits (from left to right, 10, 15, 20 and 30%). On the x-axis, effect sizes are in standard deviations and
correspond to the absolute value of the average size effect.
doi:10.1371/journal.pgen.1002496.g004
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enable the production of large quantities of sequence data on large
numbers of individuals, allowing for the cost-effective identification of
rarevariants. Thesedatawillenableresearcherstoinvestigatetherole
that rare variants play in disease etiology, in addition to uncovering
functional variants. Our results may provide guidance in the
planning, analysis and interpretation of these large-scale initiatives.
Materials and Methods
Ethics statement
The work described in this manuscript represents a re-use of
data and no new human interventions were conducted. No
additional IRB approvals were sought for this specific portion of
the work. The Committee on Ethics in Clinical Research, CHUV,
Lausanne University, Lausanne, Switzerland approved the
original protocols for sample collection.
Study sample
The subjects used in this paper are a subset of the CoLaus study,
a population-based study of 6,188 Lausanne residents aged 35 to
75 years [29].
Sanger sequencing data
Sanger sequence data for the exons and flanking regions of
seven genes including PLA2G7 from 1,998 individuals were
provided by GlaxoSmithKline (GSK). Methods for performing
the sequencing for the PLA2G7 gene and the additional 6 genes
have been described [30]. The identity of the remaining genes was
not disclosed for proprietary reasons. Sanger sequencing has a low
error rate and is considered a gold-standard for comparison to
high-throughput sequencing studies [31,32]. For simplicity, and
since rare variants are not expected to be in high linkage
disequilibrium (LD) with surrounding variants, we imputed the
missing values of each rare variant independently from others
based on the computed MAF. The percentage of missing
genotypes per variant in a gene ranged from 3% to 11%, with
an average of 5.5% individual missing genotype information per
variant, across all genes (Table 2). All non-polymorphic base-pair
markers were removed from the sequence data.
All seven genes contained both rare and common variants: the
number of polymorphic variants ranged from 29 to 128, and the
proportion of variants with a MAF#1% ranged from 81% to
93%. The majority of these variants were extremely rare, with an
average of 55% of all variants across all genes being singletons.
Table 2 and Table 3 describe the allelic frequencies, and rare
variant distribution of all seven genes. We used these known
genotypes combined with phenotype simulations to compare
several commonly-used and novel statistical methods developed
for rare variants and continuous phenotypes.
Parameters influencing rare variant associations with
complex traits
We developed two simulation sets to illustrate the power of a
variety of commonly-held hypotheses about the possible effects of
rare variants on complex traits. In the first set, we tested collapsing
Figure 5. Dichotomous traits: Relationship between effect size, proportion of causal variants, and power, when causal variants only
have a deleterious effect. Each box corresponds to a different proportion of causal variants involved in the relationship between rare variants and
continuous traits (from left to right, 10, 15, 20 and 30%). On the x-axis, effect sizes are in standard deviations and correspond to the absolute value of
the average size effect.
doi:10.1371/journal.pgen.1002496.g005
Power of Rare Variant Methods
PLoS Genetics | www.plosgenetics.org 8 February 2012 | Volume 8 | Issue 2 | e1002496and weighting designs and a range of general concepts about the
potential role of rare variants, whereas in the second set, we varied
the effect and the proportion of causal variants in across a grid of
values.
Control simulation sets
We proposed different phenotype simulation scenarios to
explore popular hypotheses regarding the mechanism by which
rare variants could influence complex disorders, namely (a) the
assumption that risk of disease increases with more rare alleles
(collapsing design), (b) the assumption that the magnitude of the
effect depends on MAF (such as equation (1) in [17] for the
weighting design), and (c) performance when a mixture of
deleterious and protective causal rare variants influences pheno-
types (Table 1). Here we describe the motivation behind our
choice of scenarios. Scenario 1, the null model, contains no causal
variants. Scenario 2 assumes that any rare variant increases the
risk of disease, which reflects the hypothesis underlying many of
the proposed statistical methods. Scenario 3 investigates a mixture
of common and rare causal variants, Scenario 4 investigates a
mixture of deleterious and protective effects, and Scenarios 5 and
6 explore the assumption that variants with lower MAF have
larger effect. In these cases, the effects were derived from equation
1 in [17].
In our simulation of phenotypes, the following rules were
applied in all scenarios. We assumed that all non-carriers of a
causal allele (deleterious or protective) variant have a normally
distributed trait with mean zero and variance of one, using a
standard normal random variable. When one or more common
variant(s) is/are assumed to have a deleterious effect, and an
individual is carrying at least one of these causal alleles, we
randomly drew a phenotypic value from a normal distribution
having a mean of 20.07 and a standard deviation of 1.01, which
allows for an effect typically identified in GWAS studies of
continuous traits [33,34,35]. When a rare variant is assumed to be
deleterious, carriers of at least one rare causal allele had a
phenotypic value randomly sampled from a normal distribution
with mean at 21.64, and standard deviation of 0.2. Relative to the
phenotype distribution of individuals with no causal variants, these
means correspond to the bottom 5% of the distribution. Similarly,
to model protective effects of a rare variant, the assigned effect was
normal with mean +1.64 and a standard deviation of 0.2. Such
effects for rare variants have been observed in the lipid literature
[36,37].
Deleterious variants were randomly sampled from the pool of
variants for each simulation. Rare variants were defined as those
having a MAF 1%, and common variants were defined as .1%.
While other thresholds can be used, GWAS have often used a 1%
threshold to define rare variants [35]. We allowed all rare variants
to be possibly causal, including singletons. Table 1 summarizes the
parameters investigated.
By varying hypotheses about the sampling of causal variants and
their effect, we created these 6 simulation scenarios. We randomly
generated a set of 250 phenotypes per individual, per scenario, per
gene. In each case, we randomly selected causal variants
associated with the traits, and then randomly generated a set of
Figure 6. Dichotomous traits: Relationship between effect size, proportion of causal variants, and power, when causal variants are
a mixture of protective and deleterious effects. Each box corresponds to a different proportion of causal variants involved in the relationship
between rare variants and continuous traits (from left to right, 10, 15, 20 and 30%). On the x-axis, effect sizes are in standard deviations and
correspond to the absolute value of the average size effect.
doi:10.1371/journal.pgen.1002496.g006
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iteration.
Systematic simulation sets
In our second series of simulations, we varied the proportion of
causal rare variants and their average effect on the phenotype
across a grid of values, i.e., where proportions (10, 15, 20, and
30%) of causal rare (MAF#1%) variants were combined with
values (0.5, 0.75, 1, 1.25, 1.5, 2, and 2.5 standard deviations) for
the mean effects. We also report in Table 4 the proportion of
variance explained by rare variants for each combination of
proportion of causal rare variants and their effect. An individual
carrying at least one rare causal allele has their phenotype value
chosen randomly from a normal distribution with one of these
seven means and with a standard deviation of 0.2. All 28
combinations between the proportion of causal (four values) and
effect (seven values) were simulated for the seven genes. Two
hundred and fifty sets of phenotypes were generated.
Multiple-testing was taken into account for single-marker test
analyses, using a conservative approach with Bonferroni correc-
tion for the number of single-nucleotide polymorphisms (SNPs)
tested. As for other rare variant methods, permutation was used to
control for type-I error in all statistical methods. Alpha level was
set to 0.05.
We also simulated dichotomous phenotypes by assuming
selection from the extremes of a quantitative distribution. In each
of the 196 scenarios presented above for continuous traits, we have
defined cases as being the 500 individuals with the lowest
continuous phenotypes, and the controls as being the 500
individuals with the highest continuous phenotypes. This study
design allows direct comparison of the relative utility of sequencing
only the extremes of a distribution, as compared to the entire
distribution, which has considerable financial ramifications
Supporting Information
Text S1 Details on the WOD method, additional details on how
the phenotypes were simulated for each scenario, and QQ plots
under the null hypothesis for all methods, and for genes 6 and 7.
(DOCX)
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